Eva Sarma


Eva joined 3i in 2006 and is a Director specialising in originating and executing private equity investments across a broad range of sectors in the UK.

Her recent deals include 3i’s investment in JMJ Associates; the dividend recapitalisation of Mayborn; the re-financing of ESG, following the sale of Inspicio’s Inspectorate business to Bureau Veritas; 3i’s investment in Agent Provocateur; and 3i’s investment in Euro-Druckservice. Eva sits on the Board of Mayborn.

Prior to 3i, Eva worked at Merrill Lynch in investment banking focusing on the healthcare sector, where her transactions included the IPO of Hikma Pharmaceuticals and the Swiss listing of Speedel. Eva started her career at PricewaterhouseCoopers.

Eva holds a masters degree in Engineering from Cambridge University.